Seres Therapeutics

Research demonstrates that gut microbiota significantly influences cancer treatment outcomes, with disrupted gut bacteria associated with resistance to immunotherapies and chemotherapy.

Seres Therapeutics will present new biomarker data at ASCO 2025 showing SER-155's potential to promote immune reconstitution following allogeneic hematopoietic stem cell transplantation.

• Kymera Therapeutics has appointed Noah Goodman, MBA, as Chief Business Officer to lead business development strategy for its targeted protein degradation platform focused on immunological diseases. • Goodman brings extensive experience from leadership roles at Chroma Medicine, nChroma Bio, Cadent Therapeutics, and Seres Therapeutics, where he specialized in business development and strategic partnerships. • Kymera is pioneering oral small molecule degrader medicines with "biologics-like activity" and has already advanced its first protein degrader into clinical trials for immunological conditions.

• The microbiome therapeutics landscape shows remarkable growth with over 140 companies actively developing 180+ pipeline drugs, spanning various disease areas and therapeutic approaches. • Recent clinical advances include promising results from MaaT Pharma's Phase 3 ARES study for GI-aGvHD and Vedanta Biosciences' Phase 2 CONSORTIUM study of VE303 for recurrent C. difficile infection. • Multiple innovative approaches are being pursued, including live biotherapeutic products, with companies like Microbiotica's MB097 showing potential in enhancing immunotherapy responses in cancer treatment.

RBX2660, a microbiota restoration therapy developed by Rebiotix and acquired by Ferring, has been granted Breakthrough Therapy Designation by the FDA for recurrent Clostridioides difficile infection.

Seres Therapeutics' SER-155 receives Breakthrough Therapy designation from the FDA for reducing bloodstream infections (BSIs) in allo-HSCT patients.